Hamilton J A, Lingelbach S, Partridge N C, Martin T J
Endocrinology. 1985 Jun;116(6):2186-91. doi: 10.1210/endo-116-6-2186.
The plasminogen activator (PA) activity of clonal rat osteogenic sarcoma cell (phenotypically osteoblast) and of osteoblast-rich rat calvarial cells is shown to be increased by treatment with the bone-resorbing hormones, PTH, 1,25-dihydroxyvitamin D3, prostaglandin E2, and epidermal growth factor. Dose-dependent increases were observed, after a lag period of 4 to 8 h. Stimulated and control PA activities were inhibited by actinomycin D and cycloheximide but not by cytosine arabinoside. Glucocorticoid hormones prevented the hormone stimulation, but other steroids did not. Calcitonin had no effect either on basal or on hormone-treated PA activity. Isobutyl-methylxanthine alone increased PA activity and enhanced responsiveness to PTH and to prostaglandin E2. These data point to a common pathway in the actions upon osteoblasts of several hormones with diverse initial cellular actions and raise the possibility that the PA/plasmin system may contribute to cellular mechanisms of bone turnover.
克隆大鼠骨肉瘤细胞(表型为成骨细胞)和富含成骨细胞的大鼠颅骨细胞的纤溶酶原激活剂(PA)活性经骨吸收激素甲状旁腺激素(PTH)、1,25 - 二羟维生素D3、前列腺素E2和表皮生长因子处理后显示增加。在4至8小时的延迟期后观察到剂量依赖性增加。放线菌素D和环己酰亚胺可抑制刺激后的和对照的PA活性,但阿糖胞苷无此作用。糖皮质激素可阻止激素刺激,但其他类固醇则不能。降钙素对基础PA活性或激素处理后的PA活性均无影响。单独使用异丁基甲基黄嘌呤可增加PA活性并增强对PTH和前列腺素E2的反应性。这些数据表明几种具有不同初始细胞作用的激素对成骨细胞的作用存在共同途径,并增加了PA/纤溶酶系统可能参与骨转换细胞机制的可能性。